Document Detail

Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective.
MedLine Citation:
PMID:  23628963     Owner:  NLM     Status:  Publisher    
Hepatocellular carcinoma (HCC) is a complex disease with a poor prognosis. Incidence and mortality rates are increasing in many geographical regions, indicating a need for better management strategies. Among several risk factors for HCC, the most common are cirrhosis because of chronic hepatitis B virus or hepatitis C virus infection and alcohol consumption, obesity, and diabetes. In some patients, combined risk factors present additional challenges to the prevention and treatment of HCC. Screening and surveillance of high-risk populations varies widely by geographic regions, and access to optimal surveillance is critical for early diagnosis. The treatment choice for HCC depends on the cancer stage, patient performance status, and liver function and requires a multidisciplinary approach and close cooperation among specialists for the best patient outcomes. Despite advances in surgical treatments and locoregional therapies, recurrence and liver failure remain significant challenges. The pathogenesis of HCC is a multistep and complex process, wherein angiogenesis plays an important role. The multikinase inhibitor sorafenib is the only approved targeted agent for advanced HCC, although promising results have been obtained with other targeted agents and combinations, and the results of ongoing trials are eagerly awaited. Clinical trials with rigorous study designs, including molecular classification and validation of new molecular biomarkers, are required to improve the personalized treatment of HCC. This article provides an overview of HCC and was developed through a review of relevant literature, clinical trial data, and updated clinical guidelines.
Massimo Colombo; Jean-Luc Raoul; Riccardo Lencioni; Peter R Galle; Jessica Zucman-Rossi; Rafael Bañares; Daniel Seehofer; Peter Neuhaus; Philip Johnson
Related Documents :
6528943 - Invasive malignant melanomas lacking competence for metastasis.
23621233 - Genistein reinforces the inhibitory effect of cisplatin on liver cancer recurrence and ...
15948743 - Twelve-year follow up of a randomized prospective trial comparing bacillus calmette-gue...
Publication Detail:
Journal Detail:
Title:  European journal of gastroenterology & hepatology     Volume:  25     ISSN:  1473-5687     ISO Abbreviation:  Eur J Gastroenterol Hepatol     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-4-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9000874     Medline TA:  Eur J Gastroenterol Hepatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  639-651     Citation Subset:  -    
a1st Division of Gastroenterology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, University of Milan, Milan bDivision of Diagnostic Imaging and Intervention, University of Pisa, Pisa, Italy cPaoli-Calmettes Institute, Marseille dInserm U674, IUH, Paris Descartes University, LabEx Immuno-Oncology, Sorbonne Paris Cité, Paris, France eUniversity Medical Center, Mainz fCharité Campus Virchow, Berlin, Germany gHealth Research Institute of the Hospital Gregorio Marañón, Networked Biomedical Research Center-Hepatic and Digestive Diseases (CIBERehd), Complutense University, Madrid, Spain hCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Predicting how cells spread and migrate: focal adhesion size does matter.
Next Document:  Recurrent severe alcoholic hepatitis: clinical characteristics and outcomes.